Safety and Efficacy of Trastuzumab BS

Pfizer

Status: Completed

Conditions: Gastric Cancer

Treatments: Drug: TRASTUZUMAB BS

Study type: Observational

Funder types: Industry

Identifiers

NCT04181333

B3271007

Details and patient eligibility

About

To confirm the safety and efficacy of this drug under the actual use

Enrollment: 8 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with unresectable advanced/recurrent gastric cancer who are confirmed to have HER2 overexpression and started treatment with this drug*
• Patients who receive this drug* for the first time after this drug* is launched * Not including the biological product, HERCEPTIN, and biosimilars of HERCEPTIN other than this drug

Exclusion criteria

• not specified in this study

Trial design

8 participants in 1 patient group

TRASTUZUMAB BS

Description:

Unresectable Advanced/Recurrent HER2-Overexpressing Gastric Cancer patients injected TRASTUZUMAB BS

Treatment:

Drug: TRASTUZUMAB BS